Oncotarget

Research Papers:

Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases

George D. Wilson _, Matthew D. Johnson, Samreen Ahmed, Paola Yumpo Cardenas, Inga S. Grills and Bryan J. Thibodeau

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:25957-25970. https://doi.org/10.18632/oncotarget.25409

Metrics: PDF 658 views  |   HTML 876 views  |   ?  


Abstract

George D. Wilson1,2, Matthew D. Johnson1,4, Samreen Ahmed2, Paola Yumpo Cardenas3, Inga S. Grills1 and Bryan J. Thibodeau2

1Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA

2Beaumont BioBank, William Beaumont Hospital, Royal Oak, MI, USA

3Cancer Genetics Program, William Beaumont Hospital, Royal Oak, MI, USA

4Department of Radiation Oncology, McLaren Health Care, Macomb, MI, USA

Correspondence to:

George D. Wilson, email: george.wilson@beaumont.edu

Keywords: non-small cell lung cancer; brain metastases; next generation DNA sequencing; targeted agents; radiotherapy

Received: January 15, 2018     Accepted: April 24, 2018     Published: May 25, 2018

ABSTRACT

Introduction: This study explores the hypothesis that dominant molecular oncogenes in non-small cell lung cancer (NSCLC) are associated with metastatic spread to the brain.

Methods: NSCLC patient groups with no evidence of metastasis, with metastatic disease to a non-CNS site, who developed brain metastasis after diagnosis, and patients with simultaneous diagnosis of NSCLC and metastatic brain lesions were studied using targeted sequencing.

Results: In patients with brain metastasis versus those without, only 2 variants (one each in BCL6 and NOTHC2) were identified that occurred in ≥ 4 NSCLC of patients with brain metastases but ≤ 1 of the NSCLC samples without brain metastases. At the gene level, 20 genes were found to have unique variants in more than 33% of the patients with brain metastases. When analyzed at the patient level, these 20 genes formed the basis of a predictive test to discriminate those with brain metastasis. Further analysis showed that PI3K/AKT signaling is altered in both the primary and metastases of NSCLC patients with brain lesions.

Conclusion: While no single variant was associated with brain metastasis, this study describes a potential gene panel for the identification of patients at risk and implicates PI3K/AKT signaling as a therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25409